Trial · NCT02690714
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 48 Weeks. | Plasminogen (Human) Intravenous | Total Visible/Non-Visible lesions resolved (%) | 34 | Lesions | |
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 48 Weeks. | Plasminogen (Human) Intravenous | Total Visible/Non-Visible lesions improved (%) | 10 | Lesions | |
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 48 Weeks. | Plasminogen (Human) Intravenous | Not applicable (not assessed) | 3 | Lesions | |
| Number and Percentage of Particpants Who Achieved the Target Plasminogen Activity Trough Levels for at Least 3 Measurements in 12 Weeks During Segment 2 | Plasminogen (Human) Intravenous | 15 | Participants | ||
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 12 Weeks | Plasminogen (Human) Intravenous | Total Visible/Non-Visible lesions resolved | 26 | Number of Lesions | |
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 12 Weeks | Plasminogen (Human) Intravenous | Total Visible/Non-Visible lesions improved | 14 | Number of Lesions | |
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 12 Weeks | Plasminogen (Human) Intravenous | Total Visible/Non-visible unchanged | 2 | Number of Lesions | |
Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 12 Weeks | Plasminogen (Human) Intravenous | Not applicable/Not assessed | 5 | Number of Lesions | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 0 = Not assessed: Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 1 = Very much improved: Week 12 | 11 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 2 = Much improved : Week 12 | 4 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 3 = Minimally improved : Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 4= No change : Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 5 = Minimally worse : Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 6 = Much worse : Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 12 | Plasminogen (Human) Intravenous | CGI score 7 = Very much worse : Week 12 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 48 | Plasminogen (Human) Intravenous | CGI Score 0= Not assessed: Week 48 | 0 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 48 | Plasminogen (Human) Intravenous | CGI Score 1= Very much improved: Week 48 | 13 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 48 | Plasminogen (Human) Intravenous | CGI Score 2= Much improved: Week 48 | 2 | Participants | |
| Clinical Global Impression-Global Improvement (CGI-I) Scores at Week 48 | Plasminogen (Human) Intravenous | CGI Score 3= Minimally improved: Week 48 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02690714/results